{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:58Z","timestamp":1756166458223,"version":"3.44.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome that is caused primarily by immune-mediated destruction of hematopoietic stem cells. Traditional treatment relies on immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CSA). However, the toxicity and limited availability of ATG have spurred interest in ATG-free regimens. This case report describes a 28-year-old male with SAA who was treated with a combination of CSA, danazol, and hetrombopag (HPAG). The patient presented with pancytopenia and a hypocellular bone marrow, thus meeting the SAA criteria. He received CSA (5 mg\/kg\/day), HPAG (started at 10 mg and increased to 15 mg\/day), and danazol (400 mg\/day). Hematologic assessments using the NIH criteria revealed a partial response at 3 months and a complete response at 6 months, with reduced proportions of active T-cell subclones and no severe adverse events. This case suggests that the combination of CSA, HPAG, and danazol is effective in treating SAA, and a large-scale clinical trial is warranted to further confirm these promising results.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1609771","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T05:26:38Z","timestamp":1756099598000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuting","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.19236","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline","volume":"204","author":"Kulasekararaj","year":"2024","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2109965","article-title":"Severe aplastic anemia working party of the european society for and T. Marrow: eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-407684","article-title":"Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party","volume":"119","author":"Marsh","year":"2012","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000499065","article-title":"Current treatment patterns of aplastic anemia in China: A prospective cohort registry study","volume":"142","author":"Zhu","year":"2019","journal-title":"Acta Haematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1007\/s00277-025-06307-z","article-title":"Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database","volume":"104","author":"Stempel","year":"2025","journal-title":"Ann Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.83","article-title":"Nontransplant therapy for bone marrow failure","volume":"2016","author":"Townsley","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00395-2","article-title":"Activity and safety of eltrombopag in combination with cyclosporin A as first\u2212line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study","volume":"11","author":"Scheinberg","year":"2024","journal-title":"Lancet Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00003-6","article-title":"Consideration of ATG-free therapy with eltrombopag and cyclosporine for severe aplastic anaemia","volume":"11","author":"Groarke","year":"2024","journal-title":"Lancet Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05910-w","article-title":"Comparison of efficacy of eltrombopag combined with immunosuppression in the treatment of severe aplastic anemia and very severe aplastic anemia: real-world data and evidence","volume":"103","author":"Li","year":"2024","journal-title":"Ann Hematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2109965","article-title":"Eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1163-x","article-title":"Danazol as first-line therapy for aplastic anemia","volume":"90","author":"Jaime-Perez","year":"2011","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0126925","DOI":"10.1371\/journal.pone.0126925","article-title":"Immunosuppressive therapy in patients with aplastic anemia: a single-center retrospective study","volume":"10","author":"Jalaeikhoo","year":"2015","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2020.03.009","article-title":"Prognostic factors of cyclosporine A combined with androgen in the treatment of transfusion dependent non-severe aplastic anemia","volume":"41","author":"Liu","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04153-9","article-title":"Long-term follow-up of a novel immunosuppressive strategy of cyclosporine alternatively combined with levamisole for severe aplastic anemia","volume":"99","author":"Huo","year":"2020","journal-title":"Ann Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1818-9","article-title":"Outcome of a novel immunosuppressive strategy of cyclosporine, levamisole and danazol for severe aplastic anemia","volume":"102","author":"Wang","year":"2015","journal-title":"Int J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2020.11.002","article-title":"Efficacy and safety of eltrombopag in aplastic anemia: A multi-center survey in China","volume":"41","author":"Yang","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1372-18","article-title":"Cyclosporine therapy in patients with transfusion-independent non-severe aplastic anemia: A retrospective analysis","volume":"58","author":"Matsuda","year":"2019","journal-title":"Intern Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390708","article-title":"Intrinsic impairment of CD4(+)CD25(+) regulatory T cells in acquired aplastic anemia","volume":"120","author":"Shi","year":"2012","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0329","article-title":"Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production","volume":"108","author":"Zeiser","year":"2006","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2022.02.013","article-title":"Efficacy of stanozolol and danazol in the treatment of non-severe aplastic anemia and their effects on CD4(+)CD25(+)Foxp3(+) regulatory T cells","volume":"43","author":"Li","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02450-0","article-title":"Adding eltrombopag to intensive immunosuppressive therapy for severe aplastic anaemia may help adult patients achieve outcomes similar to paediatric patients","volume":"39","author":"Yang","year":"2025","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00277-025-06335-9","article-title":"The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia","volume":"104","author":"Li","year":"2025","journal-title":"Ann Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/ejh.14418","article-title":"Comparison of hetrombopag and eltrombopag added to first-line immunosuppressive therapy in severe aplastic anemia","volume":"115","author":"Zhang","year":"2025","journal-title":"Eur J Haematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-021-01047-9","article-title":"A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221085197","article-title":"A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy","volume":"13","author":"Peng","year":"2022","journal-title":"Ther Adv Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1609771\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T05:26:41Z","timestamp":1756099601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1609771\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2025.1609771"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1609771","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"article-number":"1609771"}}